Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial f… Read more
Bellerophon Therapeutics Inc (BLPH) - Total Liabilities
Latest total liabilities as of September 2023: $1.26 Million USD
Based on the latest financial reports, Bellerophon Therapeutics Inc (BLPH) has total liabilities worth $1.26 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bellerophon Therapeutics Inc - Total Liabilities Trend (2012–2022)
This chart illustrates how Bellerophon Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bellerophon Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Bellerophon Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEDION
MU:MDN
|
Germany | €270.79 Million |
|
Plastic Omnium
STU:EZM
|
Germany | €5.57 Billion |
|
DAI NIPPON PRINTING
BE:DNP
|
Germany | €709.06 Billion |
|
IHI Corp
BE:IWJ
|
Germany | €1.77 Trillion |
|
UNITED UTILITIES GR
MU:UUEC
|
Germany | €13.60 Billion |
|
IBA (IOB.SG)
STU:IOB
|
Germany | €491.32 Million |
Liability Composition Analysis (2012–2022)
This chart breaks down Bellerophon Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bellerophon Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bellerophon Therapeutics Inc (2012–2022)
The table below shows the annual total liabilities of Bellerophon Therapeutics Inc from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $5.40 Million | +2.76% |
| 2021-12-31 | $5.26 Million | -56.16% |
| 2020-12-31 | $11.99 Million | +25.99% |
| 2019-12-31 | $9.52 Million | -34.38% |
| 2018-12-31 | $14.50 Million | -63.19% |
| 2017-12-31 | $39.40 Million | +236.50% |
| 2016-12-31 | $11.71 Million | +45.05% |
| 2015-12-31 | $8.07 Million | -22.78% |
| 2014-12-31 | $10.45 Million | -46.04% |
| 2013-12-31 | $19.37 Million | +33.93% |
| 2012-12-31 | $14.46 Million | -- |